FDA OKs Medtronic's third HF (heart failure) device:
This article was originally published in Clinica
Executive Summary
The US FDA has given Medtronic the go-ahead to market its third cardiac resynchronisation therapy (CRT) product for treating heart failure (HF). The InSync III cardiac resynchronisation therapy system features a new function called "sequential biventricular pacing", which allows physicians to independently programme and control the sequence of contractions of both ventricles of the heart. The ability to adjust the pacing sequence of the ventricles can help doctor's improve the heart's performance, Medtronic says.